Sun Pharma is currently trading at Rs. 501.00, up by 0.20 points or 0.04% from its previous closing of Rs. 500.80 on the BSE.
The scrip opened at Rs. 502.00 and has touched a high and low of Rs. 509.00 and Rs. 499.40 respectively. So far 15638 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 539.90 on 05-Dec-2011 and a 52 week low of Rs. 392.05 on 09-Feb-2011.
Last one week high and low of the scrip stood at Rs. 509.00 and Rs. 492.70 respectively. The current market cap of the company is Rs. 52037.99 crore.
The promoters holding in the company stood at 63.72% while Institutions and Non-Institutions held 25.48% and 10.81% respectively.
Sun Pharmaceutical Industries - US arm - Caraco Pharmaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for its generic dexmedetomidine hydrochloride injection. Dexmedetomidine is a sedative and anesthetic medication, and provides sedation without causing respiratory depression.
The tentative approval is for 100 microgram/ml strength of the injection marketed as Precedex by Hospira Inc in the US.
Recently, Sun Pharmaceutical Industries’ subsidiary had been granted an approval from USFDA for its abbreviated new drug application to market a generic version of Ultram ER, Tramadol hydrochloride extended release tablets.
Sun Pharmaceutical Industries manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |